Report of Foreign Issuer (6-k)
May 07 2019 - 6:10AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of May 2019
Commission File Number: 001-36349
MediWound Ltd.
(Translation of registrant’s name into English)
42 Hayarkon Street
Yavne, 8122745 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __
EXPLANATORY NOTE
On May 7, 2019, MediWound Ltd. (the “Company”) issued a press release entitled “MediWound Enters into Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid
®
in North America”. A copy of this press release is attached to this Form 6-K as Exhibit 99.1.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
MEDIWOUND LTD.
|
|
|
|
|
|
Date: May 7, 2019
|
By:
|
/s/
Sharon Malka
|
|
|
Name:
|
Sharon Malka
|
|
|
Title:
|
Chief Executive Officer
|
|
EXHIBIT INDEX
The following exhibit is filed as part of this Form 6-K:
Exhibit
Description
4
MediWound (NASDAQ:MDWD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MediWound (NASDAQ:MDWD)
Historical Stock Chart
From Sep 2023 to Sep 2024